09:01 AM EST, 11/10/2025 (MT Newswires) -- Exact Sciences ( EXAS ) said Monday the waiting period for its license agreement with Freenome under the US Hart-Scott-Rodino Antitrust Improvements Act expired Monday.

The exclusive license to Freenome's blood-based colorectal cancer screening tests in the US remains subject to it receiving first-line US FDA approval, Exact Sciences ( EXAS ) said.

Shares of the company were up 2% in recent Monday premarket activity.